<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714233</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB # 09354</org_study_id>
    <nct_id>NCT00714233</nct_id>
  </id_info>
  <brief_title>Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Treatment of Polycystic Ovary Syndrome (POS) in Overweight Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24 week study to compare the use of Metformin, birth control pills and a carefully planned
      intensive lifestyle program that includes weight loss and exercise. These approaches will be
      compared to placebo (a pill that contains no active substances. Metformin, birth control
      pills and the lifestyle management program will be used on this research study to compare
      their ability to:

        1. reduce fasting glucose levels

        2. reduce androgen hormone levels

        3. improve sex steroid binding, and

        4. improve lipids (fatty substances in the blood)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a condition associated with irregular menstrual cycles,
      (due to lack of regular ovulation), and evidence of elevated androgen (male hormone) levels,
      such as unwanted hair growth or acne. This condition often becomes recognized at the time of
      puberty. The standard treatment for this condition is oral contraceptive pills, which are
      used not for contraception, but to cause a regular, monthly bleeding pattern.

      Many adolescents with PCOS have increased levels of insulin, a hormone that controls the
      body's sugar balance. These increased insulin levels may play a role in the development of
      polycystic ovary syndrome. There are several medications now available, which can decrease
      the insulin levels by improving the action of insulin in the body. Metformin is one of these
      drugs. Metformin is a drug currently used in the management of diabetes to control blood
      sugar. It is hoped that by lowering the insulin levels some of the symptoms of polycystic
      ovary syndrome, such as the lack of regular periods and unwanted hair growth, can be reversed
      or diminished.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification</measure>
    <time_frame>24 week</time_frame>
    <description>The measure is to determine a number of successfully recruited overweight or obese adolescents to a randomized trial of lifestyle therapy in the community of Rochester, NY</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss in Lifestyle Intervention Group</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>In the adolescent women assigned to the lifestyle program, did the intervention program obtain weight reduction as measured by change in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Free Androgen Index (FAI)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Secondary measures of reduction in androgen measures of the different treatment arms. This is a ratio of total testosterone to sex hormone binding globulin (SHBG). The lower values correlate with lower amount of free testosterone. FAI &lt;4 is consistent with a normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SHBG</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Measurement of SHBG by treatment group pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride Concentration by Treatment Group</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in triglyceride measures pre and post intervention as representative of lipid changes by treatment group; metformin, lifestyle intervention, oral contraceptive or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in fasting glucose concentration by treatment group pre to post intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Contraceptive Pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lifestyle modification program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to active metformin arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 425mg. capsules, 2 capsules BID x 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive Pills (Yasmin)</intervention_name>
    <description>Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Yasmin oral COntraceptive tabs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Modification</intervention_name>
    <description>weekly classes x 24 weeks for training in diet, exercise and behavior modification skills</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to the active metformin arm. 2 capsules BID x 24 weeks.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>pharmacy matched placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menstrual irregularity defined as cycle length &gt; 45 days

          -  Overweight as BMI &gt; 25

          -  Clinical evidence of hirsuitism or acne

          -  Testosterone &gt; 50ng/dL

        Exclusion Criteria:

          -  History of diabetes mellitus

          -  History of Cushing's disease

          -  History of hyperprolactinemia

          -  Untreated hypo or hyperthyroidism

          -  History of adrenal hyperplasia

          -  Significant renal impairment

          -  Received oral contraceptives, estrogen or progestin or other drugs known to effect
             lipoprotein metabolism within 2 months of starting the study

          -  Exercise &gt; 10 hours per week
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Hoeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <results_first_submitted>April 8, 2011</results_first_submitted>
  <results_first_submitted_qc>August 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2011</results_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Kathleen M. Hoeger, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Overweight Adolescent Girls</keyword>
  <keyword>Irregular Menstrual Cycles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Oral Contraceptive</title>
          <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
        </group>
        <group group_id="P3">
          <title>Lifestyle Counseling</title>
          <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
        </group>
        <group group_id="P4">
          <title>Placebo to Metformin</title>
          <description>randomized to placebo pill identical to active metformin arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Oral Contraceptive</title>
          <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
        </group>
        <group group_id="B3">
          <title>Lifestyle Counseling</title>
          <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
        </group>
        <group group_id="B4">
          <title>Placebo to Metformin</title>
          <description>randomized to placebo pill identical to active metformin arm</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="1.7"/>
                    <measurement group_id="B2" value="15.4" spread="1.4"/>
                    <measurement group_id="B3" value="15.4" spread="1.2"/>
                    <measurement group_id="B4" value="15.4" spread="1.7"/>
                    <measurement group_id="B5" value="15.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification</title>
        <description>The measure is to determine a number of successfully recruited overweight or obese adolescents to a randomized trial of lifestyle therapy in the community of Rochester, NY</description>
        <time_frame>24 week</time_frame>
        <population>Analysis was a description of number of recruited subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive</title>
            <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle Counseling</title>
            <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Metformin</title>
            <description>randomized to placebo pill identical to active metformin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification</title>
          <description>The measure is to determine a number of successfully recruited overweight or obese adolescents to a randomized trial of lifestyle therapy in the community of Rochester, NY</description>
          <population>Analysis was a description of number of recruited subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Loss in Lifestyle Intervention Group</title>
        <description>In the adolescent women assigned to the lifestyle program, did the intervention program obtain weight reduction as measured by change in BMI</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>Analysis per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Lifestyle Program</title>
            <description>Subjects enrolled in a nutrition and exercise program</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss in Lifestyle Intervention Group</title>
          <description>In the adolescent women assigned to the lifestyle program, did the intervention program obtain weight reduction as measured by change in BMI</description>
          <population>Analysis per protocol</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired t-test to analyze BMI at baseline and 24 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Free Androgen Index (FAI)</title>
        <description>Secondary measures of reduction in androgen measures of the different treatment arms. This is a ratio of total testosterone to sex hormone binding globulin (SHBG). The lower values correlate with lower amount of free testosterone. FAI &lt;4 is consistent with a normal range.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>analysis per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Group assigned to metformin with free androgen index measured</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive</title>
            <description>group assigned to oral contraceptive for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Lifestle</title>
            <description>Those assigned to a nutrition and exercise program</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Metformin</title>
            <description>Matched to metformin pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Free Androgen Index (FAI)</title>
          <description>Secondary measures of reduction in androgen measures of the different treatment arms. This is a ratio of total testosterone to sex hormone binding globulin (SHBG). The lower values correlate with lower amount of free testosterone. FAI &lt;4 is consistent with a normal range.</description>
          <population>analysis per protocol</population>
          <units>total T/SHBG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.2"/>
                    <measurement group_id="O2" value="-16.7" spread="8"/>
                    <measurement group_id="O3" value="-13.7" spread="10.9"/>
                    <measurement group_id="O4" value="1.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SHBG</title>
        <description>Measurement of SHBG by treatment group pre and post intervention</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive</title>
            <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle Counseling</title>
            <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Metformin</title>
            <description>randomized to placebo pill identical to active metformin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SHBG</title>
          <description>Measurement of SHBG by treatment group pre and post intervention</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="8.6"/>
                    <measurement group_id="O2" value="77" spread="38.4"/>
                    <measurement group_id="O3" value="17.6" spread="18.3"/>
                    <measurement group_id="O4" value="2" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride Concentration by Treatment Group</title>
        <description>Change in triglyceride measures pre and post intervention as representative of lipid changes by treatment group; metformin, lifestyle intervention, oral contraceptive or placebo</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive</title>
            <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle Counseling</title>
            <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Metformin</title>
            <description>randomized to placebo pill identical to active metformin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Concentration by Treatment Group</title>
          <description>Change in triglyceride measures pre and post intervention as representative of lipid changes by treatment group; metformin, lifestyle intervention, oral contraceptive or placebo</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.3" spread="24.1"/>
                    <measurement group_id="O2" value="4.6" spread="41"/>
                    <measurement group_id="O3" value="2.2" spread="36.4"/>
                    <measurement group_id="O4" value="-6.6" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <description>Change in fasting glucose concentration by treatment group pre to post intervention</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive</title>
            <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
          </group>
          <group group_id="O3">
            <title>Lifestyle Counseling</title>
            <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Metformin</title>
            <description>randomized to placebo pill identical to active metformin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <description>Change in fasting glucose concentration by treatment group pre to post intervention</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="10.3"/>
                    <measurement group_id="O2" value="6.9" spread="8.7"/>
                    <measurement group_id="O3" value="0.4" spread="7.2"/>
                    <measurement group_id="O4" value="-1.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Randomized to Metformin 1700mg daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Oral Contraceptive</title>
          <description>Randomized to Oral Contraceptive Pills for 24 weeks. Monitored monthly for compliance</description>
        </group>
        <group group_id="E3">
          <title>Lifestyle Counseling</title>
          <description>lifestyle modification program consisting of nutritional counseling and dietary counseling meeting weekly</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Metformin</title>
          <description>randomized to placebo pill identical to active metformin arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen M Hoeger MD MPH</name_or_title>
      <organization>University of Rochester</organization>
      <phone>5852757891</phone>
      <email>Kathy_hoeger@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

